Necrostatin-1 - CAS:4311-88-0 - CAS号查询_生物试剂_化学试剂_分析试剂

中文名称:	Necrostatin-1 热销
英文名称:	Necrostatin-1
别名:	5-(1H-Indol-3-ylmethyl)-3-methyl-2-thioxo-4-Imidazolidinone,5-(Indol-3-ylmethyl)-3-methyl-2-thio-Hydantoin
CAS No:	4311-88-0	分子式:	C₁₃H₁₃N₃Os	分子量:	259.33
CAS No:	4311-88-0
分子式:	C₁₃H₁₃N₃Os
分子量:	259.33
MDL:	MFCD00056916

安全技术说明书(PDF) MSDS(PDF) 点击下载产品说明书(PDF) 点击下载技术规格说明书(PDF)

N10035 Necrostatin-1 ≥98%(HPLC) (psaitong)

相关产品

Pyrido[3,4-f]-1,4-oxazepine-9-carbonitrile, 4-(3,3-difluoro-2,2-dimethyl-1-oxopropyl)-2,3,4,5-tetrahydro-
CAS No：2252271-93-3
GSK547
CAS No：2226735-55-1
Necrostatin-5
CAS No：337349-54-9
PK68
CAS No：2173556-69-7
Necrostatin-34
CAS No：375835-43-1
GSK963
CAS No：2049868-46-2

包装规格：

10mg 100mg 1g in glass bottle

溶解性：

溶于DMSO(>10 mg/mL ) -20°C

产品描述：

基本信息

产品编号：N10035
产品名称：Necrostatin-1
CAS:	4311-88-0	储存条件	粉末	-20℃	四年

分子式：	C13H13N3Os		溶于液体	-80℃	六个月
分子量	259.33			-20℃	一个月
化学名：
Solubility (25°C)	体外	DMSO	52mg/mL warmed with 50ºC water bath (200.51mM)
		Ethanol	Insoluble
		Water	Insoluble
	体内（现配现用）	5% DMSO+45% PEG 300+ddH2O	10mg/mL
＜1mg/ml表示微溶或不溶。
普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。

制备储备液

浓度溶液体积质量	1mg	5mg	10mg
1mM	3.8561mL	19.2805mL	38.5609mL
5mM	0.7712mL	3.8561mL	7.7122mL
10mM	0.3856mL	1.9280mL	3.8561mL
50mM	0.0771mL	0.3856mL	0.7712mL

生物活性

产品描述	一种坏死细胞死亡通路抑制剂。
靶点/IC50	RIP1 (293T cells)	RIP1 (293T cells)
	490nM(EC50)	490nM(EC50)
体外研究	Necrostatin-1 (Nec-1) efficiently inhibits the TNFα-induced necrotic death of L929 cells, which does not require exogenous caspase inhibitors.Necrostatin-1 (Nec-1) prevents radiocontrast media (RCM)-induced dilation of peritubular capillaries, suggesting a novel role unrelated to cell death for the RIP1 kinase domain in the regulation of microvascular hemodynamics and pathophysiology of contrast-induced AKI (CIAKI).Necrostatin-1 (Nec-1) (30µM) increases the survival of cardiomyocyte progenitor cell (CMPCs) by inhibiting necrotic cell death.
体内研究	Necrostatin-1 (Nec-1) induces tubular bilation and affects the kinetics of the dilation of peritubular capillaries after RCM application. Upon a single intraperitoneal application of a single dose of Necrostatin-1 (1.65mg/kg body weight, i.p.) 15 minutes before RCM, the return to baseline levels is prevented within the observation period.

推荐实验方法(仅供参考)

激酶实验：

RIP1 激酶检测

RIP1 的磷酸化需要其激酶活性。FLAG标记的野生型(WT)或RIP1(K45M) 突变体失活激酶的表达结构转染到293T细胞中，在有[γ-32P]ATP存在时，RIP1激酶实验在30°C下进行30分钟。样品进行SDS-PAGE，通过放射自显影可观察到RIP1带。对放射性带的相对强度进行量化，并显示比率。在激酶反应的同时，珠样本使用anti-RIP1抗体进行Western Blot分析，确保与激酶反应中等量的蛋白。

细胞实验:

C6 (3×105 cells/well) and U87 (1.5×105 cells/well) glioma cells are seeded onto 96-well microplate and cultured 24h. PBS is added into the control group and Shikonin is added into experimental group to reach the final concentration. Cellular viability is assessed using an MTT assay after Shikonin treatment at indicated time point. The absorbance value (A) at 570nm is read using an automatic multi-well spectrophotometer. Two groups of glioma cells from the same cell line are treated with Shikonin at lower or higher concentration,respectively; other two groups of glioma cells are treated 1h with 100µM Necrostatin-1 or 40µM z-VAD-fmk prior to co-incubation with Shikonin at indicated concentration.Additionally,another two groups of glioma cells are treated only with 100µM Necrostatin-1 or 40µM Z-VAD-fmk at corresponding time point.

动物实验:

Mice

8-10 week old male C57BL/6 mice (average weight approx.23g) are used. Mice receive intravenous application of 200μL PBS or radiocontrast media (RCM) via the tail vein. A single dose of Z-VAD-fmk (10mg/kg body weight) or Necrostatin-1 (1.65mg/kg body weight) is applied intraperitoneally 15 min. before RCM-injection. Mice are harvested another 24 hours after RCM-application (48 hours after reperfusion). Blood samples are obtained from retroorbital bleeding and serum levels of urea and creatinine are determined.

保存条件：

-20℃

UN码：

HazardClass：

危害声明：

安全说明：

搜索质检报告(COA)

参考文献 & 客户发表文献